Accepted for/Published in: JMIR Formative Research
Date Submitted: Feb 7, 2023
Date Accepted: Apr 23, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Assessment of feasibility, acceptability, usability and satisfaction of a mobile therapeutic attention solution for treatment-resistant schizophrenia: m-RESIST project
ABSTRACT
Background:
In the European Union, around 5 million people are affected by psychotic disorders, and between 30-50% of people with schizophrenia have treatment-resistant schizophrenia (TRS). Mobile interventions may be effective in preventing relapses, increasing treatment adherence and managing some of the symptoms of schizophrenia. People with schizophrenia seem willing and able to use smartphones to monitor their symptoms and engage in therapeutic interventions. mHealth studies have been performed with other clinical populations, but not in TRS samples.
Objective:
The purpose of this study was to present the 3-month prospective results of the m-RESIST solution. This study aimed to assess feasibility, acceptability, usability and satisfaction in TRS patients after using the m-RESIST solution.
Methods:
The study was carried out at Sant Pau Hospital (Barcelona, Spain), Semmelweis University (Budapest, Hungary) and Sheba Medical Center & Gertner Institute of Epidemiology and Health Policy Research (Ramat-Gan, Israel). The m-RESIST solution consisted of a smartwatch, an app and a web platform, delivered to TRS patients and assisted by mental healthcare providers (psychiatrists and psychologists). Metrics for feasibility, self-assessments for acceptability and satisfaction, and online assessments for usability were performed.
Results:
The sample was composed of 39 TRS patients. Patients’ acceptance of m-RESIST ranged from moderate to high. Regarding user experience, patients indicated that m-RESIST facilitated easier and quicker communication with clinicians and made them feel more protected and safe. Patients’ satisfaction was generally good: 69% considered the quality of service as good or excellent, and 71.2% would use it again.
Conclusions:
The m-RESIST solution was well accepted by patients in terms of acceptability, usability and satisfaction. These results offer an encouraging starting point concerning mHealth technologies in TRS patients. The m-RESIST solution has contributed to TRS treatment with a new modular program based on novel technology. Clinical Trial: Trial Registration: ClinicalTrials.gov NCT03064776; https://clinicaltrials.gov/ct2/show/record/NCT03064776
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.